A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
- Status
- TERMINATED
- Phase
- PHASE2
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE3
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Status
- TERMINATED
- Phase
- PHASE2
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Status
- TERMINATED
- Phase
- PHASE3
A Study of BGB-11417 in Participants With Myeloid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
- Status
- TERMINATED
- Phase
- PHASE1
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
- Status
- TERMINATED
- Phase
- PHASE1
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1